Dry Eye Symptom Comparison 1-Month After Lasik Flap Creation With A New Femtosecond Laser Versus Ifs
Published 2022
- 40th Congress of the ESCRS
Reference: PP06.12
| Type: Free paper
| DOI:
10.82333/kesk-1270
Authors:
Raghav Malik* 1
, Brian Schwam 2
, Mahipal Sachdev 1
, Ritika Sachdev 1
, Michal Laron 3
, Andrew Voorhees 3
, Hong Fu 3
, Ying Wang 3
, Luis Vargas 4
1Cataract & Refractive Surgery,Centre For Sight,New Delhi,India, 2Johnson & Johnson Surgical Vision,Jacksonville,United States, 3Johnson & Johnson Surgical Vision,Milpitas,United States, 4Johnson & Johnson Surgical Vision,Irvine,United States
Purpose
To evaluate dry eye symptoms 1-month after Laser In-situ Keratomileusis (LASIK) flap creation with a new femtosecond laser versus iFS.
Setting
This clinical trial is part of a new femtosecond laser development project and is performed at 2 clinical sites in India. This is a single arm, bilateral prospective paired treatment study.
Methods
A prospective, multicenter, open-label, randomized paired clinical study assessing dry eye symptoms 1-month after LASIK in 84 subjects was performed. For each subject, SPEED questionnaire for the assessment of dry eye was performed monocularly pre-operatively and 1-month after LASIK surgery. The total SPEED score is the sum of frequency and severity scores for all symptoms over a range from 0 to 28. A lower total SPEED score represents less frequent and/or less severe symptoms. A score of 0 to 15 reflects none to moderate dry eye symptoms.
Results
Pre-operatively the mean SPEED questionnaire score was 0.5 with a standard deviation (SD) of 1.29 for both the new femtosecond laser and iFS eyes. One month post LASIK the mean SPEED questionnaire score slightly increased to 1.4 (SD 3.60) and 1.3 (SD 3.31) for iFS and the new femtosecond laser, respectively.
Conclusions
The small insignificant increase in SPEED questionnaire score shows that dry eye symptoms after LASIK flap performed with both iFS and the new femtosecond laser are minimal. The higher SD compared to pre-operative values shows that a very small percentage of patients do exhibit moderate symptoms 1-month after surgery.